Pan American Silver Corp. Common Stock vs 22nd Century Group Inc — how do they compare? Pan American Silver Corp. Common Stock trades at $46.27 (market cap $18.72B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Pan American Silver Corp. Common Stock is far larger — about 30112.4× 22nd Century Group Inc's market cap, and Pan American Silver Corp. Common Stock pays a 1.62% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pan American Silver Corp. Common Stock for 1 Days and 22nd Century Group Inc for 32 Days on average.
| PAAS | XXII | |
|---|---|---|
Market Cap | $18.72B | $621.67K |
Volume | 2,957,838 | 45,625 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $68.70 | $483.00 |
52-Week Low | $33.20 | $0.80 |
Typical Hold Time | 1 Days | 32 Days |
Enterprise Value | $17.86B | -$3.69M |
Dividend Yield | 1.62% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Pan American Silver is a mining company focused on silver and gold production in the Americas. It also explores and develops precious metals properties.
Read more on PAAS →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →